The views an industry trade group and a medical technology firm have on adverse event reporting requirements neeeded in the proposed “additional condition for nonprescription use” rule in the US track in some areas but diverge on an important point.
The Consumer Healthcare Products Association supports an alternative reporting mechanism the Food and Drug Administration is considering, which would require...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?